Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupIndolent LymphomasDiseaseHairy Cell LeukemiaSubgroupBRAF V600E mutationICD10C91.4-MeSHLeukemia, Hairy CellSequenceCLAD5,6 followed by RITU375, HCL, A (PID865) -|- B (PID866)RITU375/VEMU960 - RITU375, HCL, A (PID1802) -|- B (PID1803)ChemotherapyChemo-substanceBendamustineCladribineInterferon alpha-2aMoxetumomab PasudotoxPentostatinRituximabVemurafenibChemo-substanceBendamustineCladribineInterferon alpha-2aMoxetumomab PasudotoxPentostatinRituximabVemurafenibChemo-substanceBendamustineCladribineInterferon alpha-2aMoxetumomab PasudotoxPentostatinRituximabVemurafenibChemo-substanceBendamustineCladribineInterferon alpha-2aMoxetumomab PasudotoxPentostatinRituximabVemurafenibNo. Substances12 RadiotherapySupportive therapySupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCimetidineCotrimoxazoleDexamethasoneDimetindenGranisetronParacetamolPegfilgrastimPrednisoloneNo. Substances3467Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapyseveral possibleTherapy phaseConsolidationInductionReinductionTherapy intentiondisease controlpalliativeRisksAnemia Hb below 8g/dlArthalgiaCapillary Leak SyndromeDiarrheaEmetogenicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaHemolytic Uremic SyndromeHepatotoxicityHyperbilirubinemiaHypertensionHypophosphatemiaIncrease AminotransferasesInfectionsInfusion ReactionLeukopeniaLymphopeniaMyalgiasNeutropeniaPyrexiaQTc Time ExtensionRashRenal FailureThrombocytopenia below 50 000/µl only studiesPublicationAuthorBenz RBurotto MElse MGrever MKreitman RKreitman RJRavandiRobak TThomas DATiacci Evon Rohr ADiseaseHaarzelleukämie, Drittlinie, ECOG 0-2HaarzellleukämieHaarzellleukämie (Varianten), Erst- und ZweitlinieHaarzellleukämie, aktive Erkrankung, ECOG 0-3Haarzellleukämie, BRAF-V600E Mut +, vorbehandelt (z.T. mehrfach)Haarzellleukämie, BRAF-V600E Mutation, refraktär gegen Purinanaloga, oder ein früheres Rezidiv nach PurinanalogaHaarzellleukämie, Erstlinie, ECOG 0-2Haarzellleukämie, therapieresistent oder rezidiviert.Haarzellleukämie, Zweitlinie nach Nukleosidanalogon, ECOG 0-2Haarzellleukämie Erstdiagnose oder Rezidiv nach nicht Cladribin-haltiger Vortherapie, ECOG 0-2Haarzellleukämie Erstlinie, ECOG 0-3refraktäre oder rezidivierende HCL nach Pentostatin oder CladribintherapieOriginDepartment of Hematology, Medical University of Lodz, PALGDepartment of Leukemia and Hematopathology, University of Texas, MD Anderson Cancer Center, USAInstitute of Hematology, Ospedale Santa Maria della Misericordia, University of Perugia, Italy, HCL-PG03Institute of Hematology – CREO, Ospedale Santa Maria della Misericordia, University of Perugia, ItalyKantonsspital MünsterlingenLaboratory of Molecular Biology, Clinical Center, Bethesda, MarylandNational Cancer Institute, National Institutes of Health, Bethesda, Maryland, USANational Cancer Institute, NIH, Bethesda, MarylandOncology Center, Klinik Hirslanden, Zürich, SchweizSection of Haemato-Oncology, Royal Marsden Hospital/Institute of Cancer Research, Sutton, UKThe National Cancer Institute, Bethesda, USAThe University of Texas M. D. Anderson Cancer Center, HoustonProtocols in Revision 14 protocols foundProtocols under revision.Cladribine 0.12, Hairy Cell Leukemia (PID862)Cladribine 0.14, Hairy Cell Leukemia (PID536)Cladribine 0.15 / Rituximab 375, classic Hairy Cell Leukemia and variants (PID864)Cladribine 5.6 followed by Rituximab 375, Hairy Cell Leukemia, Part A (PID865)Cladribine 5.6 followed by Rituximab 375, Hairy Cell Leukemia, Part B (PID866)Interferon Alpha-2a 3 million, Hairy Cell Leukemia (PID551)Moxetumomab Pasudotox 0.04, Hairy Cell Leukemia (PID1713)Pentostatin 4 / Rituximab 375, Hairy Cell Leukemia (PID839)Pentostatin 4, Hairy Cell Leukemia (PID537)Rituximab 375 / Bendamustine 90, Hairy Cell Leukemia (PID1712)Rituximab 375 / Vemurafenib 960 - Rituximab 375, Hairy Cell Leukemia, Part A (PID1802)Rituximab 375 / Vemurafenib 960 - Rituximab 375, Hairy Cell Leukemia, Part B (PID1803)Rituximab 375, Hairy Cell Leukemia (PID538)Vemurafenib 960, Hairy Cell Leukemia (PID539)